Roche/AbbVie team scores ‘breakthrough’ FDA OK of leukemia drug

Richard Pazdur

Roche and Abbvie grabbed an accelerated approval to market their ‘breakthrough’ cancer drug venetoclax as a new treatment for patients with chronic lymphocytic leukemia who have a chromosomal abnormality called 17p deletion.

The drug will be sold as Venclexta, which targets B-cell lymphoma 2 (BCL-2) protein.

“These patients now have a new, targeted therapy that inhibits a protein involved in keeping tumor cells alive,” said Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “For certain patients with CLL who have not had favorable outcomes with other therapies, Venclexta may provide a new option for their specific condition.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

A spokesperson for AbbVie tells me that Venclexta will cost about $109,500 for a one-year supply. "In determining the price of our product, we took a number of factors into account including the overall market dynamics, the benefits of the therapy to patients, the cost effectiveness of treatment and the value that the product brings to off-setting short-term and long-term costs," the company noted. 

Venetoclax had racked up three breakthrough drug designations from the FDA, which has been whisking the drug along the regulatory path with its VIP program for top cancer drugs in the pipeline. This therapy is expected to earn in the neighborhood of $2 billion a year.

For Roche and its big subsidiary Genentech, the approval marks the latest in a series of advances on the oncology front. But it’s particularly significant for AbbVie, which paid $21 billion for Pharmacyclics last year in a deal that gave it a 50% stake in the CLL drug Imbruvica. Now it’s looking at making that part of a best-in-class choice as a combo with venetoclax in CLL.

The drug makers gained an approval based on a quick, single arm study with 106 patients. About 4 out of 5 of those patients experienced a complete or partial remission of their cancer. The 17p deletion is confirmed through the use of an approved companion diagnostic, fitting neatly into Roche’s plans to concentrate on targeted therapies.

- here's the FDA release

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.